Back to search
FDAFDA · Food and drugs·Recall number Z-2976-2026

Beckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mL

Published August 26, 2026 · Recall initiated: July 13, 2026

Summary

FDA records medical device Class II recall Z-2976-2026, published August 26, 2026 and initiated July 13, 2026. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Reported quantity: 55 units; Lot: Lots: 2597, 2627, 2709/UDI: 00842768023293. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Due to unacceptable precision performance exhibited in certain lots of the Emit 2000 Quinidine Assay, which may lead to erroneously elevated quinidine measurements, creating risk of sub-optimal patient treatment, including potential life-threatening cardiac arrhythmias or inadequate antimalarial therapy.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
Worldwide - US Nationwide distribution in the state of CA and the country of Italy.
Lot
Lots: 2597, 2627, 2709/UDI: 00842768023293
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Beckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mL recalled?

Yes. FDA published recall Z-2976-2026 on August 26, 2026. Reported hazard: Due to unacceptable precision performance exhibited in certain lots of the Emit 2000 Quinidine Assay, which may lead to erroneously elevated quinidine measurements, creating risk of sub-optimal patient treatment, including potential life-threatening cardiac arrhythmias or inadequate antimalarial therapy.

What should I do if I have this product?

Voluntary: Firm initiated · Letter